Literature DB >> 619631

Pancreatic hypersecretion in liver disease.

J A Gregg, M M Sharma.   

Abstract

Abnormally large duodenal aspirates have been reported in a large percentage of patients with cirrhosis of the liver. The source of this fluid has been variously ascribed to the liver and/or pancreas. The present study was undertaken to clarify its source. Eleven patients with cirrhosis of the liver and one with cholestatic hepatitis underwent an intraductal secretin test during endoscopic cannulation of the pancreatic duct. Six patients with cirrhosis had pancreatic hypersecretion ranging from 7.8 to 26.0 ml/min, while three patients demonstrated low secretory flow rates. Bile flow was negligible or nonexistent in ten patients, while in two others, larger but unmeasurable amounts of bile secretion were present. This study conclusively demonstrates that pancreatic hypersecretion may occur in patients with cirrhosis during secretin stimulation. Impaired metabolism of secretin or the associated pancreatic hypersecretion of early pancreatitis may be responsible for this finding.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 619631     DOI: 10.1007/bf01072568

Source DB:  PubMed          Journal:  Am J Dig Dis        ISSN: 0002-9211


  12 in total

1.  THE SECRETIN TEST IN PATIENTS WITH HAEMOCHROMATOSIS.

Authors:  G PERMAN; E BONERA
Journal:  Acta Med Scand       Date:  1964-06

2.  Pancreatic function in portal cirrhosis.

Authors:  A I FRIEDMAN; L K CHENG
Journal:  Am J Gastroenterol       Date:  1961-05       Impact factor: 10.864

3.  Hemochromatosis; investigation of twenty-three cases, with special reference to etiology, nutrition, iron metabolism, and studies of hepatic and pancreatic function.

Authors:  T L ALTHAUSEN; R K DOIG; S WEIDEN; R MOTTERAM; C N TURNER; A MOORE
Journal:  AMA Arch Intern Med       Date:  1951-11

4.  External pancreatic function in primary parenchymatous hepatic disease as measured by analysis of duodenal contents before and after stimulation with secretin.

Authors:  J B GROSS; M W COMFORT; E E WOLLAEGER; M H POWER
Journal:  Gastroenterology       Date:  1950-09       Impact factor: 22.682

5.  Cannulation of the ampulla of Vater.

Authors:  J A Gregg
Journal:  Am J Gastroenterol       Date:  1973-08       Impact factor: 10.864

6.  Electrolyte composition of the secretin fraction of bile from the perfused pig liver.

Authors:  W G Hardison; J C Norman
Journal:  Am J Physiol       Date:  1968-04

7.  Pancreatic function in alcoholic liver disease.

Authors:  A E Davis
Journal:  Med J Aust       Date:  1969-03-08       Impact factor: 7.738

8.  Liver disease and exocrine pancreatic function.

Authors:  M M Forell; H Stahlheber; M Otte
Journal:  Ger Med Mon       Date:  1967-10

9.  pH and concentration of pancreatic enzymes in aspirates from the human duodenum during digestion of a standard meal in patients with biliary or hepatic disorders.

Authors:  H Worning; S Müllertz; E H Thaysen; H O Bang
Journal:  Scand J Gastroenterol       Date:  1967       Impact factor: 2.423

10.  Secretion of pancreatic enzymes. 3. Response of patients with cirrhosis to secretin and pancreozymin.

Authors:  L Zieve; B Mulford
Journal:  Am J Dig Dis       Date:  1967-03
View more
  4 in total

1.  Impaired pancreatic exocrine function in rats with carbon tetrachloride-induced liver cirrhosis.

Authors:  T Ogasawara; T Inagaki; T Yamada; H Ohara; T Nakazawa; M Itoh
Journal:  Int J Pancreatol       Date:  1999-10

2.  Mechanism of pancreatic hypersecretion in dogs with obstructive jaundice.

Authors:  T Kuroda; K Yamagishi; F Iida; K Iwatsuki; S Chiba; Y Yamada
Journal:  Int J Pancreatol       Date:  1988-12

Review 3.  Laboratory tests in the diagnosis of the chronic pancreatic diseases. Part 3. Tests on pure pancreatic juice.

Authors:  H Rinderknecht; E J Boyd; K G Wormsley
Journal:  Int J Pancreatol       Date:  1987 Oct-Dec

4.  Gastrointestinal bleeding due to large bowel infiltration by chronic lymphocytic leukaemia.

Authors:  J Tucker; P G Cachia
Journal:  Postgrad Med J       Date:  1986-01       Impact factor: 2.401

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.